Abstract
The treatment of sarcoma urgently requires new, innovative therapeutic strategies. The most recent improvements in the cure of patients with localized disease have been achieved by dose-intensification, in turn paying the price of acute severe toxicity and secondary malignancies. Keeping side-effects to a minimum is an important goal for pediatric patients and this may be achieved by combining standard cytotoxic chemotherapy with targeted approaches. In addition, after first-line therapy, very limited treatment options remain for patients with disease progression, who, like patients with metastasis at diagnosis, are in urgent need of more effective drugs. The present review highlights key examples of target identification in bone sarcomas, including chimeric oncoproteins, insulin-like growth factor receptor (IGF-IR), and tumor/ microenvironment interactions. The review identifies questions and concerns that still need to be addressed before proceeding to safe clinical trials with agents against these promising new targets.
Keywords: Osteosarcoma, ewing's sarcoma, EWS-FLI1, IGF-IR, chemotherapy, bisphosphonates
Current Cancer Drug Targets
Title: Targeted Therapies in Bone Sarcomas
Volume: 9 Issue: 7
Author(s): K. Scotlandi, P. Picci and H. Kovar
Affiliation:
Keywords: Osteosarcoma, ewing's sarcoma, EWS-FLI1, IGF-IR, chemotherapy, bisphosphonates
Abstract: The treatment of sarcoma urgently requires new, innovative therapeutic strategies. The most recent improvements in the cure of patients with localized disease have been achieved by dose-intensification, in turn paying the price of acute severe toxicity and secondary malignancies. Keeping side-effects to a minimum is an important goal for pediatric patients and this may be achieved by combining standard cytotoxic chemotherapy with targeted approaches. In addition, after first-line therapy, very limited treatment options remain for patients with disease progression, who, like patients with metastasis at diagnosis, are in urgent need of more effective drugs. The present review highlights key examples of target identification in bone sarcomas, including chimeric oncoproteins, insulin-like growth factor receptor (IGF-IR), and tumor/ microenvironment interactions. The review identifies questions and concerns that still need to be addressed before proceeding to safe clinical trials with agents against these promising new targets.
Export Options
About this article
Cite this article as:
Scotlandi K., Picci P. and Kovar H., Targeted Therapies in Bone Sarcomas, Current Cancer Drug Targets 2009; 9 (7) . https://dx.doi.org/10.2174/156800909789760410
DOI https://dx.doi.org/10.2174/156800909789760410 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development
Current Cancer Drug Targets Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Abscopal Effect of Radiation Therapy and Signal Transduction
Current Signal Transduction Therapy CD133 Expressing Pericytes and Relationship to SDF-1 and CXCR4 in Spinal Cord Injury
Current Neurovascular Research Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC
Current Cancer Drug Targets TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
Current Topics in Medicinal Chemistry Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) The Future of Collateral Artery Research
Current Cardiology Reviews Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Current Medicinal Chemistry - Anti-Cancer Agents Modeling Study of Phenylsulfonylfuroxan Derivatives as P-gp Inhibitors: A Combined Approach of CoMFA, CoMSIA and HQSAR
Anti-Cancer Agents in Medicinal Chemistry Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs)
Recent Patents on Anti-Cancer Drug Discovery Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study (Supplementry Table)
Current Pharmacogenomics and Personalized Medicine Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Erythropoietin in Cancer: An Update
Current Molecular Medicine Effect of Quantitative and Semi-quantitative Elastography Methods for the Management of Borderline Lesions on Ultrasonography
Current Medical Imaging Shared Signaling Pathways Between Endocrine and Immune System Receptors: The Model of Gamma Chain
Current Signal Transduction Therapy Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor
Current Cancer Therapy Reviews